

Chinese firm Diagens Biotech unveils novel chromosomal karyotyping system

17 April 2023 | News

Delivering high-quality cell images, owing to state-of-the-art optical imaging technology and image sensors

The MetaSight G200 is a groundbreaking karyotyping system launched by China-based startup Hangzhou Diagens Biotechnology, based on high-resolution microscopy technology, capable of accurately detecting chromosomal abnormalities in humans.

This innovative system aids doctors in diagnosing and treating diseases associated with chromosomal abnormalities by automating and streamlining traditional karyotyping processes, ensuring greater accuracy and reliability.

The MetaSight G200 is the first model worldwide to be equipped with a chromosome defect recognition analysis module, which automatically labels chromosomal abnormalities.

Dr Ning Song, Founder of Diagens Biologics, stated, "The introduction of the MetaSight G200 system represents another significant breakthrough for us in the field of medical testing. This system will undoubtedly foster innovation and development within the industry, providing doctors and patients with more precise and reliable test results, ultimately contributing to the advancement of human health."

The launch of the MetaSight G200 third-generation karyotyping system signifies a major shift in global chromosomal analysis. Diagens will continue to bolster its technology research and innovation to make even greater contributions to human health.